Long-term view allows Temasek to be patient with poor performers

Singapore

TEMASEK Holdings can stay the course with its poor performers because it invests for the long term.

The point was made at Temasek's annual review on Tuesday, after shares of German life science giant Bayer had fallen by 39 per cent since April 2018, when Temasek put an additional three billion euros (S$4.8 billion) into the company.

Bayer faces massive legal bills from claims that popular weedkillers produced by its subsidiary Monsanto can cause cancer.

John Vaske, Temasek's head of agribusiness, told reporters: "We have the benefit of looking at things at a longer term. I think part of the share price decline is driven by people who don't have the luxury of that timeline and the ability to look at the uncertainties around something like the litigation issue and be as patien…